ArticleWorld journal of microbiology & biotechnology2026
Restoring ciprofloxacin efficacy via β-caryophyllene synergy for concurrent infection control and tissue regeneration.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of antimicrobial-resistant microbial infection on the wounds are considered a critical issue in delayed or non-healing wounds. Due to the scarcity of new antibiotics in the market, alternate combinational therapies are gaining interest in tackling this issue. In this study, we investigate the antimicrobial efficacy of ciprofloxacin (CIP) enhanced by the adjuvant activity of beta-caryophyllene (BCP), an efflux pump inhibitor harnessing their synergistic potential to achieve improved wound healing activity. The synergistic effect of CIP and BCP was assessed for its antimicrobial activity and evaluated for wound healing and infection control in both in vitro and in ovo models. The non-cytotoxic concentration of BCP (80 µg/mL) and varying concentrations of CIP (1.25-10 µg/mL) combination effectively reduced CIP's minimum inhibitory concentration by half and disintegrated biofilms of Staphylococcus aureus and Enterococcus faecalis. The combination increased fibroblast cell migration by 20% in in vitro compared to untreated samples. The BCP treatment modulated key wound-healing-associated genes, with upregulation of TGF-β, COL1A1, COL3A1, and FGF2, and downregulation of IL-1β and MMP-2, indicating profound wound healing activity. In the in ovo infection model, it achieved a 100% survival rate and additionally led to a 45% increase in vessel length and a 60% rise in vessel junctions in angiogenesis studies. Therefore, the combinational therapy of CIP and BCP demonstrated a dual role by effectively managing infections caused by multidrug-resistant wound pathogens and promoting wound healing. Remarkably, this approach reduced CIP dosage by 50%, thereby lowering antibiotic selective pressure and yielded complete killing of pathogens.
Indexed as
Identifiers
42429905What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.